After the second quarter of 2021 Roche Holding AG started describing its quarterly results as “good”: previously they had been “strong.” Over the following nine months, Roche’s stock price also weakened, falling by almost 13% against the NYSE Arca Pharmaceutical Index’s nearly 9% gain.
Stock Watch: Robust Diagnostics And Biosimilar Erosion Vie In Roche’s Q2
COVID-19 Testing May Support Roche Longer Than Expected
Roche’s stock price has underperformed in the last nine months in spite of a natural hedge on the strong US dollar that has troubled most other profitable pharma companies. Has Roche become a value stock?
